Oncolytic adenovirus VCN-01 turns cold tumors hot

VCN Biosciences is developing a highly selective, advanced generation of oncolytic adenoviruses.

Go to the profile of VCN Biosciences
Sep 12, 2019
0
0
Page of
Go to the profile of VCN Biosciences

VCN Biosciences

VCN Biosciences is a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses. VCN candidates are designed to obtain clinical activity after systemic administration and are able to remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules (including antibodies) and the immune system. VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma, retinoblastoma and head&neck carcinoma.

No comments yet.